Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.
The Germany-based company develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.
Biofrontera is the first German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 and is listed on the Frankfurt Stock Exchange (ticker symbol: B8F) and on the US NASDAQ (ticker symbol: BFRA).
Company Details
- Employees
- 95
- Founded
- -
- Address
- Hemmelrather Weg 201, Leverkusen,nordrhein-Westfalen 51377,germany
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- biofrontera.com
- HQ
- Leverkusen, Nordrhein-Westfalen
Biofrontera Group Questions
Biofrontera Group's website is biofrontera.com
Biofrontera Group's LinkedIn profile is https://de.linkedin.com/company/biofrontera-ag
Biofrontera Group has
95 employees.
View email and phone details for 95
employees at Biofrontera Group.
Biofrontera Group's industry is
Pharmaceutical Manufacturing
Biofrontera Group's top competitors are
Hana Pharm,
Galderma,
Verrica Pharmaceuticals,
Epigenomics Ag,
Evolus,
Biofrontera Inc.,
Neracare,
Paion Ag,
Ucb,
Co.don Gmbh.
Biofrontera Group's categories are Pharmaceutical Manufacturing
Biofrontera Group's founding year is 1997
